Prot# TED6828: An Open-Label Multi-Dose-Escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Project: Research project

Project Details

StatusFinished
Effective start/end date11/20/0811/20/11

Funding

  • Sanofi US Services Inc. (TED6828)